EMA Application withdrawn: Ixempra — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA withdrew the marketing authorization application for Ixempra (paclitaxel) from Bristol-Myers Squibb Pharma EEIG in the breast cancer indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Ixempra (ixabepilone)

Snippet

Status: Application withdrawn. Therapeutic area: Breast Neoplasms. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 31/12/2009